Clinical trials: Rosuvastatin
Dyslipidemia
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
The primary purpose of your participation in this study is to help answer the following research question(s) Whether LY2484595 in combination with a statin drug (atorvastatin, simvastatin or rosuvastatin; currently used to treat…
- Trial name
- NCT01105975
- Testing
- LY2484595, Atorvastatin, Simvastatin
- Where
- 59 sites in United States, Denmark and 4 more
- Volunteers
- 398 people
- Sponsor
- Eli Lilly and Company
Ovarian Cancer
Pilot Study of Rosuvastatin and Enoxaparin Thromboprophylaxis Following Ovarian Cancer Surgery (O-STAT Study)
This research study is studying a combination of two drug interventions called rosuvastatin and enoxaparin as a possible preventative measure against developing venous blood clots (such deep vein thrombosis or pulmonary…
- Trial name
- NCT03532139
- Testing
- Enoxaparin, Enoxaparin + Rosuvastatin, Thromboprophylaxis
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Beth Israel Deaconess Medical Center
Coronary Heart Disease
Assessment of the Lipid Lowering Effect of Rosuvastatin Compared to Atorvastatin in Subjects With Coronary Heart Disease
The purpose of this study is to compare the efficacy between two lipid lowering treatments, rosuvastatin (10-40 mg) and atorvastatin (20-80 mg) in reducing low-density lipoprotein cholesterol (LDL-C) levels after 16 weeks of…
- Trial name
- NCT00235950
- Testing
- Rosuvastatin or atorvastatin or simvastatin and clopidogrel
- Where
- 18 sites in Sweden
- Volunteers
- 255 people
- Sponsor
- AstraZeneca
Hypercholesterolemia
Compare the Efficacy of Rosuvastatin to Atorvastatin in High Risk Patients With Hypercholesterolemia
This trial is to compare the efficacy, safety and tolerability of Rosuvastatin with Atorvastatin by assessing the change of LDL-C in patients with hypercholesterolemia and history of coronary heart disease (CHD) or risk…
- Trial name
- NCT00683618
- Testing
- Rosuvastatin, Atorvastatin
- Where
- 6 sites in China
- Volunteers
- 934 people
- Sponsor
- AstraZeneca
Ischemic Stroke, Large-Artery Atherosclerosis (Embolus/Thrombosis)
Study of Predictive Factors Related to Prognosis of Patients With Ischemic Stroke Due to Large-artery Atherosclerosis
This is a single-center prospective cohort study of predictive factors related to prognosis of ischemic stroke due to large-artery atherosclerosis.
- Trial name
- NCT04847752
- Testing
- carotid artery stenting, carotid endarterectomy, Aspirin
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Tongji Hospital
Healthy
Drug Interaction Study of MGL-3196 With Rosuvastatin and Simvastatin
The purpose of this study is to determine whether MGL-3196 alters the pharmacokinetics of rosuvastatin and/or simvastatin in healthy male subjects and female subjects not of child-bearing potential.
- Trial name
- NCT02542969
- Testing
- Simvastatin, Rosuvastatin, MGL-3196
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Madrigal Pharmaceuticals, Inc.
Atherosclerosis
ROsuvastatin LOading and Clinical Outcomes Trial
The aim of the present study was to evaluate the effect of pre-procedural single high loading dose (40 mg) of rosuvastatin on the primary end-points of all cause mortality and composite of death or myocardial infarction from…
- Trial name
- ROLOCO (NCT01936805)
- Testing
- Rosuvastatin
- Where
- Turkey (Türkiye)
- Volunteers
- 299 people
- Sponsor
- Yuksek Ihtisas Hospital
Healthy
Study to Determine the Bioequivalence of Two Products Containing Rosuvastatin (20 mg/Tablet)
The purpose of this study is to determine the bioequivalence of Rosuvastatin/ Verisfield 20 mg film-coated tablets and Crestor™/ AstraZeneca 20 mg film-coated tablets.
- Trial name
- NCT02767310
- Testing
- Rosuvastatin 20 mg film-coated tablets, Crestor 20 mg film-coated tablets
- Where
- India
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Verisfield UK Ltd. Greek Branch
Coronary Artery Disease Progression
To Evaluate the Efficacy of Alirocumab for Neoatherosclerosis by Using OCT, in Comparison With Standard Statin Therapy
The aim of this study is to evaluate the efficacy of alirocumab for in-stent neoatherosclerosis by using optical coherence tomography, in comparison with standard statin therapy.
- Trial name
- POLARIS (NCT03533959)
- Testing
- Alirocumab
- Where
- Japan
- Volunteers
- 31 people
- Sponsor
- Kobe University
Essential Hypertension, Dyslipidemia
Combination of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and Dyslipidemia
The objective of this clinical study is to evaluate the efficacy and safety by comparing the fimasartan/amlodipine/rosuvastatin treatment group to the fimasartan/amlodipine treatment group and the fimasartan/rosuvastatin…
- Trial name
- FIRST (NCT03156842)
- Testing
- Fimasartan/Amlodipine, Rosuvastatin, Fimasartan/Amlodipine, Fimasartan, Rosuvastatin
- Where
- South Korea
- Volunteers
- 138 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypercholesterolaemia
A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.
This is a study to evaluate the effect on LDL-C and the safety and tolerability of FDC laroprovstat/rosuvastatin in LLT-naïve patients. Laroprovstat is a small molecule that reduces the amount of LDL-C in the blood.
- Trial name
- NCT07619131
- Testing
- Laroprovstat, Rosuvastatin 1, Rosuvastatin 2
- Where
- 152 sites in United States, Bulgaria and 9 more
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Dyslipidemia
A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin.
The purpose of the study is to assess the effect of AZD0780 on the pharmacokinetics of rosuvastatin, and to assess the safety and tolerability of AZD0780 single dose, in healthy participants administered alone and in combination…
- Trial name
- NCT05787002
- Testing
- AZD0780, Rosuvastatin
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
PCI Patients
Effectiveness of Statins on Lipid Goal Attainment and Lipid Parameters in PCI Patients
Most PCI patients are at very high cardiovascular (CV) risk, and as such here is an increased need for intensive lipid management in Percutaneous Coronary Intervention (PCI) patients and the population is well suited to…
- Trial name
- NCT02561845
- Testing
- rosuvastatin
- Sponsor
- AstraZeneca
Health, Subjective
A Drug-Drug Interaction Study of CTL0801 and CTL0802 Compared to Coadministration in Healthy Adult Volunteers
This is a two-arm, open-label, single-sequence, multiple-dose, cross-over phase 1 study to evaluate the interaction between two investigational drugs by comparing and analyzing the pharmacokinetic interaction and safety of…
- Trial name
- NCT05002244
- Testing
- CTL0801 (Azilsartan), CTL0802 (Rosuvastatin), CTL0801 (Azilsartan) + CTL0802 (Rosuvastatin)
- Where
- South Korea
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Celltrion
Diabete Mellitus, Lipid Profile
Effects of Selected Statins on Blood Glucose Levels in Healthy Volunteers
This Phase I randomized clinical trial aims to investigate the short-term effects of three commonly prescribed statins (atorvastatin, rosuvastatin, and simvastatin) at different dose levels on blood glucose homeostasis in healthy…
- Trial name
- [Statins] (NCT07378293)
- Testing
- Simvastatin (10mg, 20mg, 40mg), Rosuvastatin (5mg, 20mg, 40mg), Atorvastatin (10mg, 20mg, 40mg)
- Where
- 2 sites in Pakistan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Shaheed Benazir Bhutto University Sheringal Dir Upper
Acute Coronary Syndrome, Non ST Segment Elevation Acute Coronary Syndrome
Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population
For patients with ACS undergoing PCI, intensive lipid-lowering including PCSK9 monoclonal antibody should be started as soon as possible, that is, lower LDL-C level should be achieved as soon as possible.
- Conditions
- Acute Coronary Syndrome, Non ST Segment Elevation Acute Coronary Syndrome, Lipid Lowering, Vascular Inflammation
- Trial name
- NCT06096909
- Testing
- Tafolecimab, Cholesterol Absorption Inhibitor, Statin
- Where
- 2 sites in China
- Volunteers
- 3,684 people
- Sponsor
- China National Center for Cardiovascular Diseases
Acute Coronary Syndrome
Effects in The ApoB/ApoA-I Ratio Using Rosuvastatin and Atorvastatin in Patients With Acute Coronary Syndrome
The purpose of this study is to see if rosuvastatin compared to Atorvastatin is effective in treating ACS by decreasing the ApoB/ApoA-1 ratio and if starting statin within 24 h following the onset of the first symptoms is…
- Trial name
- NCT00296387
- Testing
- Rosuvastatin, Atorvastatin
- Where
- 102 sites in Belgium, Canada and 9 more
- Volunteers
- 1,160 people
- Sponsor
- AstraZeneca
ST Elevation Myocardial Infarction (STEMI)
Effect of Very Early and Rapid Lowering Cholesterol With Evolocumab on Left Ventricular Remodeling in Patients With Anterior STEMI Undergoing Primary PCI
For patients with anterior ST elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI), whether early application of proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors to…
- Trial name
- EVALUATE-STEMI (NCT05613426)
- Testing
- Rosuvastatin 20 mg, Evolocumab 140 mg/1 ml Subcutaneous Solution [REPATHA]
- Where
- 6 sites in China
- Volunteers
- 119 people
- Sponsor
- Henan Institute of Cardiovascular Epidemiology
Dyslipidaemia
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia
This is a randomised, double-blind, placebo-controlled, multi-centre, sequential Phase II and Phase III study that will evaluate the efficacy, safety, and PK of AZD0780 administered orally for up to 52 weeks in participants with…
- Trial name
- NCT06834932
- Testing
- Rosuvastatin Dose 1, Rosuvastatin dose 2, AZD0780
- Where
- 42 sites in China, Hong Kong
- Volunteers
- 432 people
- Sponsor
- AstraZeneca
Pre Diabetes, ASCVD
Comparison of Low-Intensity Statin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus (PROVE-DM)
This study is to evaluating the impact of low-intensity statin plus ezetimibe versus high-intensity statin therapy on risk of new-onset diabetes mellitus in patients with atherosclerotic cardiovascular disease who have…
- Trial name
- NCT05579626
- Testing
- high-intensity statin arm, low-intensity statin plus ezetimibe
- Where
- 31 sites in South Korea
- Volunteers
- 4,000 people
- Sponsor
- Seung-Whan Lee, M.D., Ph.D.